Table 1.
Demographic, clinical and serological features of patients with primary Sjögren's syndrome (pSS) enrolled for analyses on peripheral blood samples
| Number of patients | 15 |
| Age, yearsa | 56 ± 3 |
| Disease duration, yearsa | 12 ± 2 |
| Xerostomia | 14 (93) |
| Xerophthalmia | 15 (100) |
| Salivary gland enlargement | 6 (40) |
| Extraglandular manifestationsb | 10 (67) |
| Lymphoma | 0 |
| Hypocomplementemia | 10 (67) |
| Leukopenia | 2 (13) |
| Hypergammaglobulinemia | 9 (60) |
| Antinuclear antibodies | 15 (100) |
| Autoantibodies | |
| Neither anti‐Ro/SSA nor anti‐La/SSB | 3 (20) |
| Anti‐Ro/SSA only | 6 (40) |
| Anti‐Ro/SSA and anti‐La/SSB | 6 (40) |
| Rheumatoid factor | 8 (53) |
| Hydroxychloroquine 200 mg/day | 8 (53) |
| ESSDAI, median (range) | 2 (0–4) |
a
These values are reported as mean ± S.E.M. Unless otherwise stated, all other values are reported as number (percentage) of patients.
b
Eight patients with articular involvement and two patients with Raynaud's phenomenon. All other extraglandular manifestations were ruled out.